The Role of Denosumab in the Treatment of Primary Tumors of Bone.

J Hand Surg Am · Sep 2023 · Review

Wessel LE, Strike SA, Singh A, Bernthal NM, Athanasian EA

Department of Orthopaedic Surgery, University of California Los Angeles, Los Angeles, CA

Hand & Upper Extremity Orthopaedic Oncology

SUMMARY — THE REDUCTIONHand surgeons treating benign bone tumors should know denosumab can reduce pain, shrink tumor volume, and address lung metastases, even without an oncology referral.
Abstract, as published

Many hand surgeons treat benign bone tumors without referral to orthopedic oncologists. However, there have been considerable advances in medical therapy for some of these tumors, with which hand surgeons may not be as familiar. This review focuses on the mechanism and uses of denosumab in the treatment of benign tumors of bone. Although the hand surgeon may not be directly prescribing this therapy, they are often the only physician treating the patient for these conditions. As such, awareness regarding the use of this therapy in reducing pain, decreasing tumor volume, and treatment of potential lung metastases is critical to those taking on these cases without the support of an orthopedic oncologist. This article aims to familiarize hand surgeons with denosumab to help promote knowledge of this therapeutic option and the potential role of this medication in the treatment of primary bone tumors in the hand.

Featured in the 2026-06-21 issue.

← Impact of Patient and Tumor Characteristics on Range of Motio…Zone 1 Flexor Tendon Repairs: Laceration and Avulsion Injuries. →

The Reduction is a free email digest of newly published orthopaedic literature — a handful of new papers in the subspecialties you choose, each summarized like this one. Subscribe free or browse the archive.